The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Open accessAbstract
Purpose: To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods: A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results: The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective–retrospective studies that evaluated the clinical utility of biomarkers. Recommendations: In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Self-citationTumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationMolecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Self-citationUse of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Self-citationTumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Self-citationTeutsch, S. M., Bradley, L. A., Palomaki, G. E., Haddow, J. E., Piper, M., Calonge, N., Dotson, W. D., Douglas, M. P., & Berg, A. O. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e318184137c · Cited by 680
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2561 · Cited by 648
Self-citationLindström, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., Hatschek, T., Skoog, L., & Bergh, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2482 · Cited by 523
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434 · cited 1×
“This set of publications (see Data Supplement 3) included three systematic reviews and metaanalyses(16-18) and seven comparative observational studies.(19-26) Six studies addressed clinical utility, as defined in Clinical Utility section, for initiating or selecting therapy for metastatic breast cancer.”
BackgroundNiikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Self-citationMeta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer
Zhang, L., Riethdorf, S., Wu, G., Wang, T., Yang, K., Peng, G., Liu, J., & Pantel, K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1587 · Cited by 366
Evolution of Translational Omics: Lessons Learned and the Path Forward
Micheel, C., Nass, S. J., & Omenn, G. S. (2013) · Cited by 365
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2843 · Cited by 353
Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 343
Self-citationComparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
Hayes, D. F., Zurawski, V. R., & Kufe, D. W. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1542 · Cited by 319
Self-citationSimmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., & Clemons, M. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp028 · Cited by 286
Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group (2010) · Breast Cancer Research · doi:10.1186/bcr2771 · Cited by 253
Receptor conversion in distant breast cancer metastases
Hoefnagel, L. D., van de Vijver, M. J., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., Oudejans, J., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2645 · Cited by 226
(2008) · Cited by 225
Evolution of Translational Omics: Lessons Learned and the Path Forward
Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy, & Institute of Medicine (2012) · National Academies Press eBooks · doi:10.17226/13297 · Cited by 200
Dieci, M. V., Barbieri, E., Piacentini, F., Ficarra, G., Bettelli, S., Dominici, M., Conte, P. F., & Guarneri, V. (2013) · Annals of Oncology · doi:10.1093/annonc/mds248 · Cited by 196
Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
Stoecklein, N. H., & Klein, C. A. (2010) · International Journal of Cancer · doi:10.1002/ijc.24916 · Cited by 186
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
McShane, L. M., & Hayes, D. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6858 · Cited by 185
Self-citationShiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Amir, E., Clemons, M., Purdie, C. A., Miller, N., Quinlan, P., Geddie, W., Coleman, R. E., Freedman, O. C., Jordan, L. B., & Thompson, A. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.006 · Cited by 176
Finn, R. S., Press, M. F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., Williams, L. S., & Di Leo, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1925 · Cited by 164
Miles, D. W., de Haas, S. L., Dirix, L. Y., Romieu, G., Chan, A., Pivot, X. B., Tomczak, P., Provencher, L., Cortés, J., Delmar, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.69 · Cited by 157
Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
Polley, M.-Y. C., Freidlin, B., Korn, E. L., Conley, B. A., Abrams, J. S., & McShane, L. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt282 · Cited by 151
Alers, J. C., Krijtenburg, P.-J., Vissers, K. J., & van Dekken, H. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700512 · Cited by 146
Measuring the Performance of Markers for Guiding Treatment Decisions
Janes, H., PEPE, M. S., Bossuyt, P. M., & Barlow, W. E. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-4-201102150-00006 · Cited by 142
Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Rosenfeld, N., & Caldas, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1306040 · Cited by 140
Hayes, D. F., Allen, J. D., Compton, C. C., Gustavsen, G. G., Leonard, D. G. B., Mccormack, R. T., Newcomer, L. N., Pothier, K. C., Ransohoff, D. F., Schilsky, R. L., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005950 · Cited by 124
Self-citationHoussami, N., Macaskill, P., Balleine, R. L., Bilous, M., & Pegram, M. D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1632-x · Cited by 116
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Hoefnagel, L. D. C., Moelans, C. B., Meijer, S. L., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., et al. (2012) · Cancer · doi:10.1002/cncr.27518 · Cited by 93
Outcomes of interest in evidence-based evaluations of genetic tests
Botkin, J. R., Teutsch, S. M., Kaye, C. I., Hayes, M., Haddow, J. E., Bradley, L. A., Szegda, K., & Dotson, W. D. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cdde04 · Cited by 90
Kröger, N. M., Milde‐Langosch, K., Riethdorf, S., Schmoor, C., Schumacher, M. C., Zander, A. R., & Löning, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1340 · Cited by 90
Galmarini, C. M., Treilleux, I., Cardoso, F., Bernard-Marty, C., Durbecq, V., Gancberg, D., Bissery, M.-C., Paesmans, M., Larsimont, D., Piccart, M. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4741 · Cited by 69
Ginsburg, G. S., & Kuderer, N. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6114 · Cited by 48
Distinct breast cancer subtypes in women with early-onset disease across races.
Singh, M., Ding, Y., Zhang, L., Song, D., Gong, Y., Adams, S., Ross, D. S., Wang, J., Grover, S., Doval, D. C., et al. (2014) · Europe PMC (PubMed Central) · Cited by 36
Cited by
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,474
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Self-citationRugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Metadata
- Authors
- Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., Mayer, I. A., Mennel, R. G., Symmans, W. F., Hayes, D. F., & Harris, L. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-08-20
- Volume
- 33
- Issue
- 24
- Pages
- 2695-2704
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115813710
- Cited by
- 404
- References
- 43
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.